Cryptococcosis

1. Clinical Overview

Summary

Cryptococcosis is a potentially life-threatening systemic fungal infection caused by encapsulated yeasts of the Cryptococcus species complex, predominantly Cryptococcus neoformans (associated with pigeon droppings and soil) and Cryptococcus gattii (associated with eucalyptus and other trees). The infection is acquired through inhalation of aerosolized basidiospores or desiccated yeast cells from environmental sources. [1]

In immunocompetent individuals, cryptococcal infection typically causes asymptomatic or self-limited pulmonary disease. However, in immunocompromised hosts—particularly patients with advanced HIV/AIDS (CD4 count less than 100 cells/μL), solid organ transplant recipients, and those on chronic corticosteroid therapy—the organism disseminates haematogenously to the central nervous system, causing cryptococcal meningoencephalitis. This represents the most common and severe manifestation of cryptococcosis and remains a leading cause of death among people living with HIV globally, particularly in sub-Saharan Africa and Southeast Asia. [2,3]

The hallmark clinical presentation is subacute meningitis characterized by persistent headache, fever, altered mental status, and critically, raised intracranial pressure (ICP). Early recognition and aggressive management of raised ICP through serial therapeutic lumbar punctures is essential, as elevated ICP is the primary cause of early mortality. Diagnosis relies on cerebrospinal fluid (CSF) cryptococcal antigen (CrAg) testing—which has > 95% sensitivity—supplemented by India ink staining demonstrating encapsulated yeasts and fungal culture. Treatment follows a three-phase protocol: induction therapy with amphotericin B plus flucytosine for 2 weeks, consolidation with high-dose fluconazole for 8 weeks, and maintenance (secondary prophylaxis) with fluconazole until immune reconstitution. Importantly, antiretroviral therapy (ART) must be delayed by 4-6 weeks to reduce mortality from immune reconstitution inflammatory syndrome (IRIS), as demonstrated by the landmark COAT trial. [4,5]

Despite optimal treatment, mortality remains 10-25% in resource-rich settings and higher in resource-limited settings where access to amphotericin B and therapeutic lumbar puncture capacity may be limited. [6] Cryptococcal meningitis is a medical emergency requiring prompt diagnosis, antifungal therapy, and meticulous ICP management.

Key Facts at a Glance

Microbiology

• Primary species: Cryptococcus neoformans (var. grubii and var. neoformans) — immunocompromised hosts
• Secondary species: Cryptococcus gattii — can affect immunocompetent individuals, endemic in tropical/subtropical regions
• Environmental niche: Soil contaminated with bird (especially pigeon) droppings; tree hollows (eucalyptus, red oak)
• Route of infection: Inhalation of airborne propagules
• Key virulence factors: Polysaccharide capsule (antiphagocytic), melanin production (oxidative stress resistance), thermotolerance (37°C growth), laccase enzyme (CNS tropism)

Epidemiology

• Global burden: ~220,000 cases/year; ~180,000 deaths/year (81% mortality rate) [2]
• Geographic distribution: Highest burden in sub-Saharan Africa (> 70% of cases), Southeast Asia, Latin America
• Primary risk group: HIV/AIDS with CD4 less than 100 cells/μL (> 80% of cases)
• Other risk groups: Solid organ transplant recipients (2-5% incidence), chronic corticosteroid use, haematological malignancies, sarcoidosis, idiopathic CD4+ lymphopenia

Clinical Presentation

• CNS disease (85%): Subacute meningitis with headache (universal), fever (variable), altered mental status, neck stiffness (often absent in HIV)
• Pulmonary disease (10-30%): Often asymptomatic; may present as cough, dyspnoea, chest pain; imaging shows nodules, infiltrates, or effusions
• Disseminated disease: Skin (papules/nodules mimicking molluscum contagiosum), bone, prostate (reservoir for relapse)
• Raised ICP: Present in > 50% of cases; major cause of early death; requires aggressive management

Diagnosis

• CSF CrAg (lateral flow assay): Sensitivity > 95%, specificity > 98%; first-line diagnostic test [7]
• Serum CrAg: Positive in > 99% of meningitis cases; used for screening asymptomatic HIV patients with CD4 less than 100
• India ink staining: 70-80% sensitive; demonstrates encapsulated yeasts with characteristic "halo"
• CSF culture: Gold standard but takes 48-72 hours
• CSF findings: Elevated opening pressure (> 25 cm H2O), lymphocytic pleocytosis (may be minimal in advanced AIDS), elevated protein, low glucose

Treatment

• Induction (2 weeks): Amphotericin B deoxycholate 0.7-1 mg/kg/day IV + Flucytosine 100 mg/kg/day PO (divided QID)
• Alternative induction: Single high-dose liposomal amphotericin B (10 mg/kg) + flucytosine + fluconazole (investigational, resource-limited settings) [8]
• Consolidation (8 weeks): Fluconazole 800 mg/day PO (400 mg if resource-limited)
• Maintenance (secondary prophylaxis): Fluconazole 200 mg/day PO until CD4 > 200 cells/μL sustained for ≥6 months + undetectable HIV viral load
• ICP management: Serial therapeutic lumbar punctures (remove 20-30 mL CSF) to maintain opening pressure less than 20 cm H2O; ventriculoperitoneal shunt if refractory
• ART timing: Delay 4-6 weeks from diagnosis to reduce IRIS mortality (COAT trial) [4]

Prognosis

• 10-week mortality (treated): 20-25% in high-income settings; 35-70% in resource-limited settings [6]
• Poor prognostic factors: Altered mental status at baseline, high fungal burden (CSF CrAg titre > 1:1024), elevated opening pressure > 25 cm H2O, low CSF white cell count (less than 20 cells/μL), absence of headache (indicates poor inflammatory response), disseminated disease
• Long-term outcomes: With immune reconstitution on ART, long-term survival possible; risk of relapse if maintenance therapy discontinued prematurely

Clinical Pearls

"Headache in Advanced HIV = Cryptococcus Until Proven Otherwise": Any patient with HIV and CD4 less than 100 cells/μL presenting with headache should be presumed to have cryptococcal meningitis and undergo urgent lumbar puncture. The threshold for investigation must be extremely low.

"Opening Pressure Kills More Than the Fungus": Raised intracranial pressure (opening pressure > 25 cm H2O) is the single most important predictor of early death. Aggressive ICP management with daily therapeutic lumbar punctures (removing 20-30 mL CSF to reduce pressure by ~50%) is more critical than antifungal choice in the first 2 weeks. The goal is to maintain opening pressure less than 20 cm H2O.

"CrAg Screening Saves Lives": Routine serum cryptococcal antigen screening of all HIV patients with CD4 less than 100 cells/μL (even if asymptomatic) is cost-effective and recommended by WHO. CrAg-positive asymptomatic patients receive pre-emptive fluconazole, which reduces meningitis incidence by 70% and mortality by 20-30%. [9]

"India Ink Has Been Superseded": While India ink is historically famous and shows beautiful encapsulated yeasts with a "halo" appearance, CSF CrAg lateral flow assay is faster (15 minutes), more sensitive (> 95% vs 70-80%), and requires less expertise. CrAg testing is the modern standard.

"Delay ART or Increase Death": Immediate initiation of antiretroviral therapy in cryptococcal meningitis (within 1-2 weeks) significantly increases mortality compared to delayed initiation at 4-6 weeks (hazard ratio 1.73), primarily due to IRIS. This is one of the few situations where ART is deliberately delayed. [4]

"Flucytosine Is Essential But Often Unavailable": The combination of amphotericin B + flucytosine achieves superior fungal clearance and reduces 10-week mortality by 40% compared to amphotericin B alone. However, flucytosine is unaffordable or unavailable in most resource-limited settings where 90% of cases occur—a tragic gap in global health equity. [10]

"Prostate Is the Reservoir": Cryptococcus has a predilection for the prostate gland, where it can persist despite treatment. Inadequate duration of maintenance fluconazole can lead to prostatic relapse. This is why maintenance therapy must continue until immune reconstitution, not just clinical improvement.

"Corticosteroids Are Harmful, Not Helpful": Unlike bacterial meningitis (where dexamethasone reduces mortality), corticosteroids in cryptococcal meningitis do not improve outcomes and may increase mortality. They should be avoided in induction therapy but may have a role in IRIS management. [11]

Why This Matters Clinically

Cryptococcal meningitis is responsible for 15-20% of all AIDS-related deaths globally, with ~180,000 deaths annually—more than tuberculosis meningitis. [2] The majority of this burden falls on sub-Saharan Africa, where it is the most common cause of adult meningitis. Early diagnosis through low-threshold lumbar puncture and cryptococcal antigen testing, aggressive management of raised intracranial pressure, and evidence-based antifungal therapy are life-saving interventions that every clinician caring for immunocompromised patients must master. The condition is also increasingly recognized in non-HIV populations including transplant recipients, where mortality may be even higher.

---

2. Epidemiology

Global Burden and Distribution

Cryptococcosis represents a major global health problem with marked geographic variation:

Risk Factors

The overwhelming majority of cryptococcal disease occurs in the setting of profound T-cell immunodeficiency:

HIV/AIDS (Most Important)

Advanced HIV disease (CD4 less than 100) accounts for 80-90% of all cryptococcal cases globally. [3] In the pre-ART era, up to 10% of AIDS patients developed cryptococcosis. With widespread ART availability in high-income countries, incidence has decreased by > 90%, but the disease remains endemic in sub-Saharan Africa and Southeast Asia where ART coverage and virological suppression rates are lower. [15]

Other Immunocompromised States

Cryptococcus gattii — Immunocompetent Hosts

Unlike C. neoformans, C. gattii can cause severe disease in immunocompetent individuals. Endemic areas include:

• Australia (especially Northern Queensland)
• Papua New Guinea
• Vancouver Island, Canada (outbreak 1999-2015)
• Pacific Northwest USA (Oregon, Washington, California)
• Brazil, Colombia, Mexico

C. gattii infections tend to cause more pulmonary disease, larger cryptococcomas, and higher rates of neurological complications. [16]

Demographics

• Age: Peak incidence 30-50 years (reflects HIV demographics); bimodal in non-HIV disease (children with immunodeficiency syndromes; elderly on immunosuppression)
• Sex: Male predominance (60-70% of cases), likely due to HIV epidemiology rather than biological sex difference
• Socioeconomic factors: Associated with poverty, limited access to ART, delayed HIV diagnosis

Trends Over Time

In high-income countries with universal ART access, cryptococcal meningitis incidence has declined dramatically since the mid-1990s (> 90% reduction). However, global burden remains essentially unchanged because:

1. Population growth in high-burden regions
2. Ongoing HIV transmission
3. Late HIV diagnosis (40-50% present with CD4 less than 200 at diagnosis)
4. ART access and adherence challenges in resource-limited settings
5. Delayed or absent cryptococcal antigen screening programs

---

3. Aetiology and Pathophysiology

Causative Organisms

Species Complex

• Cryptococcus neoformans (90% of global cases)
  • C. neoformans var. grubii (serotype A) — most common globally
  • C. neoformans var. neoformans (serotype D) — temperate climates, Europe
  • Predominantly affects immunocompromised hosts
• Cryptococcus gattii (10% of cases; higher in endemic regions)
  • Multiple molecular types (VGI, VGII, VGIII, VGIV)
  • Can affect immunocompetent individuals
  • Associated with specific environmental reservoirs (eucalyptus trees)

Environmental Reservoir

• C. neoformans: Soil enriched with avian excreta (especially pigeon guano); high nitrogen content supports growth; worldwide distribution
• C. gattii: Tree hollows and bark of eucalyptus, oak, pine, and other species; tropical and subtropical climates
• Aerosolization of desiccated yeast cells or basidiospores (less than 2 μm diameter) allows deep alveolar penetration upon inhalation

Infection Pathway

Step 1: Inhalation and Pulmonary Deposition

• Small airborne propagules (less than 2 μm) bypass upper airway defenses and deposit in alveoli
• In immunocompetent hosts: Alveolar macrophages phagocytose and contain infection
• In immunocompromised hosts: Defective cell-mediated immunity (CD4+ T-cell deficiency) allows intracellular survival and replication

Step 2: Primary Pulmonary Infection

• Most infections are asymptomatic or mildly symptomatic
• Granuloma formation may contain infection in immunocompetent hosts (latent infection possible)
• In profound immunosuppression: Unchecked pulmonary replication leads to pneumonia or progression to dissemination

Step 3: Haematogenous Dissemination

• Extrapulmonary spread occurs via bloodstream
• Tropism for CNS, skin, bone, and prostate
• CNS predilection attributed to:
  • Absence of complement components in CSF
  • High glucose content (supports fungal metabolism)
  • Laccase enzyme production (phenoloxidase) generating catecholamines attractive to fungus
  • Limited immune surveillance

Step 4: CNS Invasion and Meningitis

• Yeasts cross blood-brain barrier (mechanism incompletely understood; transcellular migration and "Trojan horse" entry via macrophages proposed)
• Replication in subarachnoid space → meningoencephalitis
• Gelatinous pseudocysts in perivascular Virchow-Robin spaces
• Invasion of brain parenchyma → cryptococcomas (mass lesions)

Step 5: Raised Intracranial Pressure

• Primary mechanism: Impaired CSF reabsorption due to fungal polysaccharide clogging arachnoid granulations
• Secondary mechanisms: Cryptococcomas causing mass effect; hydrocephalus (communicating or non-communicating); cerebral oedema (less common)
• Opening pressure > 25 cm H2O in > 50% of cases; pressures > 40-50 cm H2O associated with severe outcomes

Virulence Factors

Cryptococcus possesses several unique virulence factors that enable pathogenicity:

Immune Response

Normal (Protective) Response

• Cell-mediated immunity (CMI) is critical for control
• CD4+ Th1 cells produce IFN-γ and IL-2 → macrophage activation
• Activated macrophages kill intracellular Cryptococcus
• Granuloma formation contains infection
• Antibody-mediated (humoral) immunity is NOT protective

Defective Response in Immunocompromised Hosts

• CD4+ T-cell depletion (HIV) → impaired Th1 response
• Calcineurin inhibitors (transplant) → impaired T-cell activation
• Corticosteroids → suppression of cell-mediated immunity and granuloma formation
• Result: Uncontrolled fungal replication and dissemination

Immune Reconstitution Inflammatory Syndrome (IRIS)

• Occurs in 10-30% of patients started on ART after cryptococcal meningitis diagnosis [17]
• Paradoxical worsening of symptoms (headache, confusion, fever) despite decreasing fungal burden
• Mechanism: Restoration of pathogen-specific immune responses → excessive inflammation
• Timing: Usually 2-8 weeks after ART initiation
• Higher risk if: ART started less than 4 weeks, high baseline fungal burden, rapid CD4 recovery

---

4. Clinical Presentation

Cryptococcal Meningoencephalitis

Cryptococcal meningitis typically presents as subacute meningitis evolving over days to weeks, in contrast to bacterial meningitis (hours) or tuberculous meningitis (weeks to months).

Symptoms

Classical Triad (NOT Reliable) Unlike bacterial meningitis (fever, headache, neck stiffness), the classical meningitis triad is present in less than 50% of cryptococcal cases, especially in HIV patients. A high index of suspicion is essential.

Signs

Raised Intracranial Pressure — Critical Recognition

[!CAUTION] RED FLAGS FOR RAISED ICP

Clinical Features:

• Severe, unremitting headache despite analgesia
• Repeated vomiting
• Progressively declining GCS or altered mental status
• Visual disturbance: blurred vision, diplopia, transient visual obscuration
• Papilloedema on fundoscopy
• Cranial nerve VI palsy

Lumbar Puncture Findings:

• Opening pressure > 25 cm H2O (normal: 10-20 cm H2O)
• Opening pressure > 40 cm H2O = severe; emergency

IMMEDIATE ACTION:

• Perform therapeutic lumbar puncture: remove 20-30 mL CSF
• Measure closing pressure (goal: reduce by ≥50% or to less than 20 cm H2O)
• Repeat opening pressure daily until pressure controlled for 2 consecutive days
• If refractory (> 3 therapeutic LPs without improvement): consider temporary lumbar drain or ventriculoperitoneal shunt

DO NOT:

• Use mannitol or acetazolamide (ineffective in cryptococcal raised ICP) [18]
• Use corticosteroids during induction (may worsen outcomes) [11]

Raised ICP is the leading cause of early death (within 2 weeks of diagnosis). Aggressive management is more important for early survival than antifungal choice. [18]

Pulmonary Cryptococcosis

Pulmonary involvement occurs in 30-50% of patients but is often asymptomatic or overshadowed by CNS disease. [19]

Clinical Presentation

Imaging Findings

Key Point: Any pulmonary cryptococcosis in an immunocompromised host requires investigation for CNS dissemination (lumbar puncture and serum CrAg even if asymptomatic for meningitis).

Disseminated Cryptococcosis

Extrapulmonary, extra-CNS involvement occurs in 10-20% of cases, usually in profoundly immunosuppressed patients.

---

5. Clinical Examination

Systematic Approach

General Inspection

• Appearance: Level of consciousness, distress, respiratory distress
• Vital signs: Temperature (may be normal), HR, BP, RR, SpO2
• Hydration status
• Evidence of wasting (advanced HIV/AIDS)

Neurological Examination

Chest Examination

• Inspection: Respiratory rate, use of accessory muscles
• Palpation: Expansion, tactile fremitus
• Percussion: Dullness (consolidation, effusion)
• Auscultation: Crackles (pneumonia), reduced breath sounds (effusion)

Skin Examination

• Look for: Umbilicated papules/nodules (disseminated cryptococcosis)
• Mimics: Molluscum contagiosum (common in HIV)
• Distribution: Face, trunk, extremities

Abdominal Examination

• Hepatosplenomegaly (disseminated disease)
• Lymphadenopathy

Stigmata of HIV/AIDS

• Oral candidiasis (suggests CD4 less than 200)
• Oral hairy leukoplakia
• Kaposi's sarcoma
• Wasting

---

6. Investigations

Initial Assessment

Immediate Investigations (All Suspected Cases)

1. Lumbar puncture with opening pressure measurement (if no contraindication)
2. HIV test (if status unknown)
3. CD4 count (if HIV-positive)
4. Serum cryptococcal antigen
5. Blood cultures (fungal and bacterial)
6. Full blood count, renal function, liver function, glucose

Lumbar Puncture — Diagnostic Cornerstone

Contraindications to LP (Perform CT Head First)

• Focal neurological signs (excluding isolated CN VI palsy)
• Reduced GCS (less than 12)
• Seizures within 7 days
• Papilloedema with signs of cerebral herniation
• Coagulopathy (platelets less than 50, INR > 1.5)

LP Technique — Critical Points

• ALWAYS measure opening pressure (using manometer with patient in lateral decubitus position, legs extended)
• Use large-gauge needle (20G or 22G) to allow CSF flow for therapeutic removal if needed
• Collect adequate CSF volume: 10-15 mL for all tests

CSF Analysis

CSF Cryptococcal Antigen Testing

• Lateral flow assay (LFA): Point-of-care test; results in 10-15 minutes; > 95% sensitivity and specificity [7]
• Quantitative titre: Dilutional testing; reported as titre (e.g., 1:1024)
  • "Titre ≥1:1024 associated with higher fungal burden and poorer outcomes"
  • Can monitor response to treatment (decreasing titres suggest response)
• False negatives: Extremely rare if performed correctly; prozone effect (false negative with very high antigen load) prevented by dilution in modern assays

India Ink Staining

• Technique: Mix CSF with India ink; encapsulated yeasts appear as clear "halos" against dark background
• Sensitivity: 70-80% (lower in HIV due to low organism burden)
• Specificity: High if performed by experienced microscopist
• Replaced by CrAg testing in modern practice but still used in resource-limited settings
• Pearls: Best visualized at 10x or 40x magnification; may be confused with lymphocytes or artefacts

Serum Cryptococcal Antigen

Blood Cultures

• Fungal blood cultures: Positive in 25-75% of disseminated cryptococcosis; lower sensitivity than CSF in meningitis
• Bacterial blood cultures: Exclude co-infection

Imaging

CT Head

Indications for CT/MRI Before LP

• Focal neurological signs
• Reduced GCS
• Recent seizure
• Papilloedema with signs of impending herniation

MRI Brain (More Sensitive)

Chest X-Ray

Additional Tests

---

7. Differential Diagnosis

Cryptococcal meningitis must be distinguished from other causes of subacute/chronic meningitis, particularly in immunocompromised hosts.

Main Differentials

Red Flags: "Do Not Miss" Diagnoses

1. Bacterial meningitis: Requires immediate empirical antibiotics (ceftriaxone + vancomycin)
2. Tuberculous meningitis: Requires immediate empirical TB treatment (RHZE + steroids) in high-risk populations
3. Herpes simplex encephalitis: Requires immediate aciclovir
4. Space-occupying lesion with impending herniation: Requires neurosurgical consultation

Approach to the Patient with Subacute Meningitis

All patients should have:

• CSF: CrAg, culture (bacterial, fungal, TB), Gram stain, Ziehl-Neelsen stain, cell count, protein, glucose
• Serum: HIV test, CrAg, syphilis serology
• Imaging: CT or MRI brain
• Blood cultures

If CrAg negative, consider:

• TB meningitis (TB PCR, culture)
• Partially treated bacterial meningitis
• Viral meningitis (enterovirus PCR)
• Neurosyphilis (CSF VDRL)
• Autoimmune/paraneoplastic (CSF oligoclonal bands, autoantibody panel)

---

8. Management

Overview of Treatment Phases

Cryptococcal meningitis management follows a three-phase protocol based on landmark trials:

1. Induction (2 weeks): High-intensity antifungals to achieve fungal clearance ("early fungicidal activity")
2. Consolidation (8 weeks): Step-down therapy to consolidate gains
3. Maintenance/Secondary prophylaxis (6-12 months or longer): Prevent relapse until immune reconstitution

Concurrent critical management:

• Aggressive raised ICP management (therapeutic LPs)
• Delayed ART initiation (4-6 weeks post-diagnosis)
• Treatment of complications (IRIS, hydrocephalus)

---

Induction Therapy (Weeks 1-2)

Goal: Rapid fungal clearance; reduce early mortality

Preferred Regimen (HIV-Associated)

Rationale: The combination of amphotericin B + flucytosine achieves superior early fungicidal activity (rate of CSF sterilization) and reduces 10-week mortality from 35% (amphotericin alone) to 24% (combination). [10] This is the gold standard induction therapy.

Alternative Regimens

Resource-Limited Settings (Flucytosine Unavailable)

Novel Approach (Under Investigation): Single high-dose liposomal amphotericin B (10 mg/kg) + flucytosine + fluconazole has shown promise in resource-limited settings (reduced nephrotoxicity, single-day infusion, cost-effective). [8] Awaiting Phase 3 trial results.

Non-HIV Cryptococcosis (Transplant, Other Immunosuppression)

Liposomal amphotericin is preferred in transplant recipients to reduce nephrotoxicity (already receiving nephrotoxic immunosuppressants). [14]

Monitoring During Induction

---

Management of Raised Intracranial Pressure

This is the most important determinant of early survival.

[!CAUTION] Raised ICP Management Protocol

Immediate (Day 1)

1. Measure opening pressure during diagnostic LP
2. If OP ≥25 cm H2O: Perform therapeutic LP
   • Remove 20-30 mL CSF
   • Measure closing pressure
   • Goal: Reduce OP by ≥50% or to less than 20 cm H2O

Ongoing (Days 2-14) 3. Daily opening pressure measurement and therapeutic LP if OP ≥25 cm H2O 4. Continue daily LPs until OP less than 20 cm H2O for 2 consecutive days 5. Then reduce frequency: alternate days → twice weekly → as needed for symptoms

Refractory Raised ICP (> 3 therapeutic LPs without sustained control) 6. Consider temporary percutaneous lumbar drain

• Allows continuous CSF drainage
• Risk: infection, CSF leak

7. Consider ventriculoperitoneal (VP) shunt [22]
   • Indications: Persistent ICP despite LPs/drain; hydrocephalus
   • Timing: Preferably after CSF sterilization (to avoid shunt infection)
   • Outcomes: Reduces mortality in refractory cases

What NOT to Do

• ❌ Acetazolamide: Not effective; may worsen metabolic acidosis [18]
• ❌ Mannitol: Not effective for cryptococcal ICP [18]
• ❌ Corticosteroids: Do NOT improve outcomes; may increase mortality [11]
• ❌ Furosemide: Not effective

Evidence: Early aggressive ICP management reduces 2-week mortality. [18] The magnitude of CSF removal (≥20 mL) correlates with symptom relief and survival.

Practical Pearls:

• Therapeutic LPs can be performed daily without harm
• Symptoms (headache, vomiting, visual disturbance) are better indicators of ICP than absolute pressure number
• Document opening and closing pressures meticulously
• If patient develops severe headache after initial improvement → ICP rising again; repeat LP

---

Consolidation Therapy (Weeks 3-10)

Goal: Consolidate fungal clearance; prevent early relapse

Evidence: High-dose fluconazole (800 mg/day) is superior to lower doses for consolidation. [5]

Monitoring:

• Clinical improvement (headache resolution, GCS improvement)
• Repeat LP at 2 weeks post-induction (optional but informative): CSF should be culture-negative
• Liver function tests (fluconazole hepatotoxicity)

---

Maintenance Therapy (Secondary Prophylaxis)

Goal: Prevent relapse; continue until immune reconstitution

Typical Duration: 6-12 months minimum; often longer

Evidence: Fluconazole is superior to itraconazole for maintenance therapy. [23]

Discontinuation Criteria (all must be met):

1. Completed induction and consolidation therapy
2. Asymptomatic (no headache, neurological symptoms)
3. CD4 count > 200 cells/μL sustained for ≥6 months (some guidelines say > 100)
4. Undetectable HIV viral load on ART
5. No evidence of active cryptococcal disease

Risk of Relapse: 2-5% per year if maintenance therapy stopped appropriately; higher if stopped prematurely

---

Antiretroviral Therapy (ART) Timing

Landmark Trial: COAT trial (Cryptococcal Optimal ART Timing) [4]

Mechanism of Harm: Immune reconstitution inflammatory syndrome (IRIS)

Current Recommendation: Delay ART initiation by 4-6 weeks from cryptococcal meningitis diagnosis. [4,5]

Exceptions:

• If CD4 less than 50 and OTHER opportunistic infections present, may consider earlier ART (week 4) after multidisciplinary discussion
• If patient already on ART when diagnosed → continue ART (do not stop)

This is one of the few situations in HIV medicine where ART is deliberately delayed.

---

Management of Immune Reconstitution Inflammatory Syndrome (IRIS)

Definition: Paradoxical worsening of cryptococcal disease after ART initiation despite microbiological improvement

Incidence: 10-30% of patients [17]

Timing: Usually 2-8 weeks after ART start (median 4 weeks)

Presentation:

• Recurrence or worsening of meningitis symptoms (headache, fever, confusion)
• New or enlarging cryptococcomas
• Lymphadenitis
• Pulmonary infiltrates
• Raised ICP

Diagnosis (all must be present):

1. ART initiated in preceding 12 weeks
2. Worsening neurological symptoms/signs
3. Decreasing CSF fungal burden (culture-negative or decreasing CrAg titre) OR stable disease on effective antifungals
4. No other alternative explanation (treatment failure, bacterial co-infection, drug toxicity)

Management:

• Continue ART (do NOT stop; survival benefit outweighs IRIS risk once it occurs)
• Continue antifungal therapy
• Manage raised ICP aggressively (therapeutic LPs)
• NSAIDs (ibuprofen, naproxen) for symptom control
• Corticosteroids (prednisone 0.5-1 mg/kg/day, taper over 4-6 weeks) if severe IRIS
  • Evidence limited; case series suggest benefit
  • Only use AFTER CSF sterilization confirmed (to avoid worsening fungal infection)

---

Special Populations

Non-HIV Immunocompromised (Transplant Recipients)

Note: Mortality is higher in non-HIV immunocompromised (30-40%) due to difficulty reversing underlying immunosuppression. [14]

Pregnancy

• Amphotericin B: Safe in pregnancy (Category B)
• Fluconazole: Teratogenic at high doses (≥400 mg/day); use lowest effective dose or consider amphotericin B monotherapy
• Flucytosine: Avoid if possible (limited data; theoretical risk)

Renal Impairment

• Amphotericin B: Nephrotoxic; consider liposomal formulation
• Flucytosine: Renally excreted; dose reduction required (monitor levels if available)
• Fluconazole: Renally excreted; dose reduction required (GFR less than 50: reduce to 50% of dose)

---

Management Algorithm — Visual Summary

                    CRYPTOCOCCAL MENINGITIS SUSPECTED
                      (HIV + CD4 less than 100 + headache)
                                   ↓
            ┌──────────────────────┴───────────────────────┐
            │                                               │
       CT HEAD FIRST?                                   LUMBAR PUNCTURE
      (if contraindication                           (Opening pressure +
       to LP: focal signs,                           CSF CrAg + India ink
       reduced GCS, seizure)                         + culture + routine)
            │                                               │
            └──────────────────────┬───────────────────────┘
                                   ↓
                        CSF CrAg POSITIVE
                   (Diagnosis confirmed)
                                   ↓
         ┌─────────────────────────┼─────────────────────────┐
         │                         │                         │
    INDUCTION                   ICP MGMT                  ART TIMING
  (Weeks 1-2)                  (Ongoing)                 (Delay 4-6 wk)
         │                         │                         │
 AmB 1 mg/kg/d IV          OP ≥25 cm H2O?            Do NOT start
      +                         ↓ YES                ART for 4-6 wk
 Fluc 100mg/kg/d PO     Therapeutic LP daily         (COAT trial)
      ×14 days            (remove 20-30mL)                 │
         │                until OP less than 20 ×2d                 │
         │                         │                       │
         ↓                         ↓                       ↓
   CONSOLIDATION            Monitor opening          START ART
    (Weeks 3-10)            pressure 2×/wk           (Week 4-6)
         │                         │                       │
 Fluconazole 800mg/d        If refractory:             Monitor for
      PO ×8 weeks           Consider VP shunt          IRIS (weeks
         │                         │                    4-12 post-ART)
         ↓                         ↓                       │
    MAINTENANCE             Continue until                 ↓
  (6-12+ months)            symptoms resolve         If IRIS: Continue
         │                                            ART + antifungals
 Fluconazole 200mg/d                                  + steroids if severe
 until CD4 > 200 ×6mo
 + undetectable VL
         │
         ↓
  STOP MAINTENANCE
   (if criteria met)

---

9. Complications

Leading Causes of Death:

1. Raised ICP (early: weeks 1-2)
2. Overwhelming fungal burden/sepsis (early)
3. IRIS (weeks 4-12 post-ART)
4. Relapse (late: months to years)

---

10. Prognosis and Outcomes

Mortality

Prognostic Factors

Poor Prognosis (Higher Mortality)

Good Prognosis (Lower Mortality)

Long-Term Outcomes

Survivors:

• Neurological sequelae: 20-40% have residual deficits (cognitive impairment, hearing loss, visual impairment, motor deficits)
• Quality of life: Reduced compared to general population; cognitive impairment impacts work/daily activities
• Immune reconstitution on ART: CD4 recovery allows discontinuation of maintenance fluconazole after 6-12 months
• Life expectancy: Near-normal if immune reconstitution achieved and adherence to ART maintained

Relapse:

• 5-15% overall
• Higher if maintenance therapy stopped prematurely or ART non-adherence
• Relapse typically occurs within 6-12 months of stopping maintenance therapy
• Management: Repeat full induction course

---

11. Prevention and Screening

Primary Prevention

Reduce Exposure (Limited Efficacy)

• Avoid areas heavily contaminated with bird droppings (pigeon roosts)
• Not practical for most patients; environmental exposure difficult to avoid

Primary Prophylaxis (Not Routinely Recommended)

• Routine antifungal prophylaxis (fluconazole) for all HIV patients with CD4 less than 100 is NOT recommended due to:
  • Cost
  • Drug resistance concerns
  • Lack of mortality benefit in clinical trials
• Exception: May consider in very high-burden settings (> 10% prevalence)

Secondary Prevention (Screening and Pre-emptive Therapy)

WHO Recommendation: Screen all HIV patients with CD4 less than 100 cells/μL for serum cryptococcal antigen, even if asymptomatic. [9]

Rationale:

• 5-15% of asymptomatic HIV patients with CD4 less than 100 are CrAg-positive (cryptococcal antigenaemia)
• Without intervention, 30-50% develop cryptococcal meningitis within 3 months
• Pre-emptive fluconazole reduces progression to meningitis by 70% and mortality by 20-30%
• Cost-effective intervention [20]

CrAg Screening Protocol:

1. Test: Serum CrAg lateral flow assay (point-of-care; results in 10 minutes)
2. If CrAg-positive:
   • Perform lumbar puncture to rule out meningitis (even if asymptomatic)
   • If LP normal (no meningitis) → Pre-emptive therapy:
     • Fluconazole 800 mg/day × 2 weeks, then 400 mg/day × 8 weeks, then 200 mg/day maintenance
   • If LP shows meningitis → Treat as cryptococcal meningitis (full induction protocol)
3. If CrAg-negative:
   • Start ART
   • Repeat CrAg if CD4 remains less than 100 and symptoms develop

Implementation: CrAg screening programs save lives and are cost-effective but require:

• Point-of-care CrAg testing availability
• Linkage to lumbar puncture facilities
• Access to fluconazole
• Patient follow-up

---

12. Key Guidelines and Evidence

Major Guidelines

Landmark Trials and Evidence

COAT Trial (2014) [4]

• Question: When to start ART in cryptococcal meningitis?
• Design: RCT, Uganda; 177 patients; early ART (1-2 weeks) vs deferred ART (5 weeks)
• Results: Early ART increased 26-week mortality (45% vs 30%; HR 1.73)
• Conclusion: Delay ART by 4-6 weeks
• Impact: Changed global practice; now standard of care

ACTA Trial (2016) [10]

• Question: Does adding flucytosine to amphotericin improve outcomes?
• Design: RCT, Africa; 721 patients; AmB alone vs AmB + flucytosine vs AmB + fluconazole
• Results: AmB + flucytosine reduced 10-week mortality from 35% (AmB alone) to 24% (combination; HR 0.62)
• Conclusion: Flucytosine essential for induction
• Impact: Established AmB + flucytosine as gold standard

Graybill et al. (2000) [18]

• Focus: Management of raised ICP
• Design: Prospective cohort; 191 patients
• Results: Therapeutic LPs (removing ≥20 mL CSF) reduced symptoms and improved survival; mannitol/acetazolamide ineffective
• Conclusion: Aggressive LP-based ICP management is life-saving
• Impact: Established therapeutic LP as standard of care

WHO CrAg Screening Evidence [9,20]

• Multiple trials show CrAg screening + pre-emptive fluconazole reduces meningitis incidence by 70% and mortality by 20-30%
• Cost-effectiveness analyses: Dominant strategy (saves costs and saves lives)

---

13. Examination Focus

High-Yield Topics for MRCP/FRACP

Common Viva Questions and Model Answers

Q1: A 35-year-old HIV-positive man presents with 2 weeks of headache and fever. CD4 count is 45 cells/μL. How would you approach this?

Model Answer: "This patient has advanced HIV disease (CD4 less than 100) and subacute meningitis symptoms, raising strong suspicion for cryptococcal meningitis—the most common cause of meningitis in this population. My immediate approach would be:

First, assess for contraindications to lumbar puncture—focal neurological signs (except isolated CN VI palsy), reduced GCS, recent seizures, or signs of raised ICP with herniation risk. If any present, I would perform CT head first.

Assuming no contraindications, I would perform lumbar puncture with opening pressure measurement (critical), and send CSF for cryptococcal antigen (highly sensitive, > 95%), India ink stain, fungal culture, routine cell count, protein, glucose, and also bacterial Gram stain and culture to exclude bacterial co-infection. I would also send blood for serum CrAg, HIV viral load, and blood cultures.

If the opening pressure is ≥25 cm H2O, I would perform therapeutic LP immediately—removing 20-30 mL of CSF to reduce pressure by at least 50%, as raised ICP is the leading cause of early death.

If CSF CrAg is positive, confirming cryptococcal meningitis, I would initiate induction therapy with amphotericin B 1 mg/kg/day IV plus flucytosine 100 mg/kg/day orally for 2 weeks, with daily opening pressure monitoring and therapeutic LPs as needed. Critically, I would delay ART initiation by 4-6 weeks based on the COAT trial, as early ART increases mortality from IRIS."

Q2: What is the management of raised intracranial pressure in cryptococcal meningitis?

Model Answer: "Raised ICP is the most important predictor of early mortality in cryptococcal meningitis and requires aggressive management.

The cornerstone is serial therapeutic lumbar punctures. I would measure opening pressure during the initial diagnostic LP. If the pressure is ≥25 cm H2O—which occurs in over 50% of cases—I perform a therapeutic LP immediately, removing 20-30 mL of CSF with the goal of reducing the opening pressure by at least 50% or to below 20 cm H2O. I measure the closing pressure to confirm adequate reduction.

I would then perform daily opening pressure measurements and therapeutic LPs for as long as the pressure remains elevated, continuing until the opening pressure is below 20 cm H2O for at least 2 consecutive days. After that, I would reduce the frequency based on symptoms and pressure trends.

If raised ICP is refractory despite multiple therapeutic LPs, I would consider a temporary lumbar drain for continuous CSF drainage, or neurosurgical consultation for a ventriculoperitoneal shunt, ideally after CSF sterilization to reduce shunt infection risk.

Importantly, mannitol and acetazolamide are NOT effective for cryptococcal raised ICP, and corticosteroids do not improve outcomes and may increase mortality, so I would avoid them."

Q3: Why is antiretroviral therapy delayed in cryptococcal meningitis?

Model Answer: "This is based on the landmark COAT trial published in the New England Journal of Medicine in 2014. The trial randomized 177 patients with cryptococcal meningitis in Uganda to either early ART—started within 1-2 weeks of diagnosis—or deferred ART at 5 weeks.

The trial was stopped early because the early ART arm had significantly higher 26-week mortality: 45% in the early group versus 30% in the deferred group, with a hazard ratio of 1.73. This represents a 73% increase in mortality with early ART.

The mechanism is immune reconstitution inflammatory syndrome, or IRIS. When ART is started while there is still significant fungal burden in the CNS, immune recovery leads to excessive inflammation that paradoxically worsens meningitis symptoms, causes further raised ICP, and increases mortality.

Based on this trial, current guidelines recommend delaying ART initiation by 4-6 weeks from the diagnosis of cryptococcal meningitis. This is one of the rare situations in HIV medicine where we deliberately delay ART, as the harm from IRIS outweighs the benefit of early immune reconstitution. After 4-6 weeks, fungal burden is typically reduced by induction and consolidation antifungals, making ART safer."

Common Mistakes That Fail Candidates

❌ Mistake 1: Starting ART immediately in cryptococcal meningitis

• Increases mortality; shows lack of awareness of COAT trial

❌ Mistake 2: Not measuring opening pressure during LP

• Misses the leading cause of death; inadequate management

❌ Mistake 3: Using mannitol or acetazolamide for raised ICP

• Ineffective in cryptococcal disease; shows dated knowledge

❌ Mistake 4: Using corticosteroids during induction

• No benefit; may harm; confusing with bacterial meningitis

❌ Mistake 5: Failing to mention flucytosine in induction therapy

• Reduces mortality by 40%; essential component

❌ Mistake 6: Not knowing CrAg screening indication (CD4 less than 100)

• WHO-recommended, high-yield, cost-effective intervention

---

14. Patient and Layperson Explanation

What is cryptococcal meningitis?

Cryptococcal meningitis is a serious infection of the tissues surrounding the brain (the meninges) caused by a fungus called Cryptococcus. This fungus is found in the environment, especially in soil contaminated with bird droppings.

Who gets it?

It mainly affects people with weakened immune systems, particularly:

• People living with HIV whose immune cell counts (CD4 counts) are very low (below 100)
• People who have had organ transplants and take medicines to suppress the immune system
• People taking long-term high-dose steroid medications

How do you catch it?

You breathe in the fungus from the environment. In people with normal immune systems, the body fights it off easily. But if your immune system is very weak, the fungus can spread through your bloodstream to your brain and cause meningitis.

What are the symptoms?

The most common symptoms are:

• Persistent, severe headache
• Fever
• Confusion or drowsiness
• Neck stiffness (though this may be absent)
• Blurred vision
• Nausea and vomiting

Symptoms usually develop gradually over days to weeks.

How is it diagnosed?

The main test is a lumbar puncture (spinal tap), where a needle is inserted into the lower back to collect a small amount of fluid from around the spinal cord. This fluid is tested for the fungal antigen (a substance produced by the fungus), which is very accurate. We also measure the pressure of the fluid, which is often high and needs treatment.

A blood test can also detect the fungus.

How is it treated?

Treatment has three phases and takes many months:

Phase 1 (2 weeks): Strong antifungal medicines given through a vein (amphotericin B) and by mouth (flucytosine). This phase requires hospitalization.

Phase 2 (8 weeks): A different antifungal medicine taken by mouth (fluconazole) at a high dose.

Phase 3 (6-12 months or longer): The same medicine (fluconazole) at a lower dose to prevent the infection from coming back. This continues until your immune system recovers.

Managing pressure on the brain: Many patients need repeated spinal taps to remove fluid and reduce dangerous pressure on the brain. This is a critical part of treatment and can be life-saving.

HIV treatment timing: If you have HIV, starting HIV medications immediately can actually make things worse by causing an immune overreaction. HIV treatment is usually delayed by about 4-6 weeks to allow the antifungal medicines to work first.

Is it serious?

Yes, cryptococcal meningitis is very serious. Even with the best treatment, about 20-25% of patients die within the first few months, and the rate is higher in countries with limited medical resources. However, with early diagnosis and aggressive treatment—especially managing the brain pressure—many people do survive and can live normal lives if their immune system recovers.

Can it be prevented?

If you have HIV and your CD4 count is below 100, you should be screened with a simple blood test for the fungus even if you feel well. If the test is positive, you can be given medicine to prevent meningitis from developing. Starting and staying on HIV treatment to keep your immune system strong is the best long-term prevention.

---

15. References

1. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016;30(1):179-206. doi:10.1016/j.idc.2015.10.006. PMID: 26897067

2. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881. doi:10.1016/S1473-3099(17)30243-8. PMID: 28483415

3. Kwon-Chung KJ, Fraser JA, Doering TL, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014;4(7):a019760. doi:10.1101/cshperspect.a019760. PMID: 24985132

4. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498. doi:10.1056/NEJMoa1312884. PMID: 24795087

5. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322. doi:10.1086/649858. PMID: 20047480

6. Shapiro AE, Ndhlovu CE, Mangu C, et al. An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies. HIV Med. 2023;24(3):251-263. doi:10.1111/hiv.13378. PMID: 36123803

7. Kwizera R, Akampurira A, Williams DA, et al. Acridine orange fluorescent microscopy is more sensitive than India ink light microscopy in the rapid detection of cryptococcosis among CrAg positive HIV patients. PLoS One. 2017;12(7):e0182108. doi:10.1371/journal.pone.0182108. PMID: 28750078

8. Jarvis JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 2022;386(12):1109-1120. doi:10.1056/NEJMoa2111904. PMID: 35320642

9. World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: WHO; 2022. Available at: https://www.who.int/publications/i/item/9789240052178

10. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa (ACTA trial). N Engl J Med. 2018;378(11):1004-1017. doi:10.1056/NEJMoa1710922. PMID: 29539937

11. Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542-554. doi:10.1056/NEJMoa1509024. PMID: 26863356

12. Lawrence DS, Boyer-Chammard T, Jarvis JN. Emerging concepts in HIV-associated cryptococcal meningitis. Curr Opin Infect Dis. 2019;32(1):16-23. doi:10.1097/QCO.0000000000000514. PMID: 30507673

13. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Med Mycol. 2019;57(2):133-150. doi:10.1093/mmy/myy086. PMID: 30329097

14. Aslam S, Rotstein C, AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13543. doi:10.1111/ctr.13543. PMID: 30900315

15. Spec A, Powderly WG. Cryptococcal meningitis in AIDS. Handb Clin Neurol. 2018;152:139-150. doi:10.1016/B978-0-444-63849-6.00011-6. PMID: 29604972

16. Chang CC, Sorrell TC, Chen SC. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2015;36(5):681-691. doi:10.1055/s-0035-1562895. PMID: 26398535

17. Balasko A, Keynan Y. Shedding light on IRIS: from pathophysiology to treatment of cryptococcal meningitis and immune reconstitution inflammatory syndrome in HIV-infected individuals. HIV Med. 2019;20(1):1-10. doi:10.1111/hiv.12676. PMID: 30362282

18. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30(1):47-54. doi:10.1086/313603. PMID: 10619732

19. Chowdhary A, Randhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update. Crit Rev Microbiol. 2012;38(1):1-16. doi:10.3109/1040841X.2011.606426. PMID: 22133016

20. Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173-2182. doi:10.1016/S0140-6736(15)60164-7. PMID: 25765698

21. Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012;26(11):1363-1370. doi:10.1097/QAD.0b013e328354b419. PMID: 22472852

22. Cornejo-Venegas G, Peña-Cadena PA, Passi GR, Narula N, Kataria R. Cerebrospinal fluid shunting for the management of cryptococcal meningitis: a scoping review. Ther Adv Infect Dis. 2024;11:20499361231225915. doi:10.1177/20499361231225915. PMID: 38333229

23. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28(2):291-296. doi:10.1086/515110. PMID: 10064246

24. Chang CC, Dorasamy AA, Gosnell BI, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24(8):e507-e523. doi:10.1016/S1473-3099(23)00731-4. PMID: 38346436

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team | Topic 734/1071